DESIGN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.51 USD | +0.45% |
|
-3.84% | +70.19% |
| May. 08 | Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 07 | Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 254M |
|---|---|---|---|---|---|
| Net income 2024 * | -58M | Net income 2025 * | -77M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 256M | Net cash position 2025 * | 198M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-4.4
x | P/E ratio 2025 * |
-3.48
x | Employees | 57 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 63.46% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -1.32% | ||
| 1 week | -4.26% | ||
| Current month | +27.56% | ||
| 1 month | +21.68% | ||
| 3 months | +93.53% | ||
| 6 months | +96.07% | ||
| Current year | +69.43% |
1 week
4.47
4.98
1 month
3.515.23
Current year
2.255.23
1 year
1.948.31
3 years
1.9428.49
5 years
1.9450.50
10 years
1.9450.50
| Managers | Title | Age | Since |
|---|---|---|---|
Pratik Shah
CEO | Chief Executive Officer | 54 | 17-12-17 |
Sean Jeffries
COO | Chief Operating Officer | 44 | 20-12-31 |
Jae B. Kim
CTO | Chief Tech/Sci/R&D Officer | 55 | 22-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pratik Shah
CEO | Chief Executive Officer | 54 | 17-12-17 |
John Schmid
BRD | Director/Board Member | 61 | 20-10-31 |
Simeon George
BRD | Director/Board Member | 46 | 20-01-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.02% | 1,487 M€ | +7.21% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 4.51 | +0.45% | 112 843 |
| 24-05-14 | 4.49 | -1.32% | 125,297 |
| 24-05-13 | 4.55 | -0.44% | 224,015 |
| 24-05-10 | 4.57 | -4.19% | 249,453 |
| 24-05-09 | 4.77 | +1.71% | 492,917 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotes
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. The Company is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its HD program is focused on the development of a potentially disease-modifying treatment for HD.
Calendar
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
4.49
USD
Average target price
6.667
USD
Spread / Average Target
+48.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +69.43% | 254M | |
| +29.03% | 49.18B | |
| -0.10% | 42.11B | |
| +49.17% | 40.37B | |
| -5.26% | 28.85B | |
| +11.48% | 26.09B | |
| -22.74% | 18.71B | |
| +9.06% | 13.26B | |
| +30.01% | 12.32B | |
| -1.51% | 11.99B |
- Stock Market
- Equities
- DSGN Stock
